- Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Dronabinol; Drug: Clonidine; Drug: Placebo
Sponsors: Mclean Hospital; Mclean Hospital; Brain and Behavior Research Foundation (formerly NARSAD)
Recruiting - verified May 2012 - Condition: Pulmonary Hypertension
Interventions: Drug: Carvedilol; Drug: Carvedilol placebo
Sponsors: The Cleveland Clinic; The Cleveland Clinic; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Conditions: Prehypertension; Stage-1 Hypertension
Interventions: Dietary Supplement: Non-fat dairy; Dietary Supplement: Add 4 servings fruit
Sponsors: University of Texas at Austin; University of Texas at Austin
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension Inclusion Criteria 1. Must be Unaffected by a Neurologica
Interventions: Drug: Carvedilol; Drug: Imatinib
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Condition: Essential Hypertension
Interventions: Drug: XOMA 985; Drug: Amlodipine Besylate; Drug: Perindopril Erbumine
Sponsors: XOMA (US) LLC; XOMA (US) LLC
Recruiting - verified March 2012 - Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Pfizer
Recruiting - verified March 2012 - Conditions: Cord Blood Transplant; Hematologic Malignancy; Inherited Metabolic Disease
Intervention: Drug: TXA127
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified March 2012 - Condition: Pregnancy
Interventions: Drug: Iloprost; Other: normal saline
Sponsors: Fertility Specialists of Houston; Fertility Specialists of Houston; Origio A/S
Recruiting - verified March 2012 - Conditions: Prehypertension; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol; Drug: Placebo
Sponsors: University of Colorado, Boulder; University of Colorado, Boulder; Forest Laboratories
Recruiting - verified May 2012 - Condition: Post-traumatic Stress Disorder
Interventions: Drug: Propranolol Hydrochloride; Other: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; Department of Defense; Northern California Institute of Research and Education
Not yet recruiting - verified May 2012 - Conditions: Tourette Disorder; Tourette Syndrome
Interventions: Drug: placebo; Drug: extended-release guanfacine (Intuniv)
Sponsors: Yale University; Yale University; New York University; University of South Florida; Shire Development LLC
Recruiting - verified May 2012 - Condition: No Condition. Assessment of Healthy Volunteers.
Interventions: Drug: mibefradil; Other: Placebo
Sponsors: Tau Therapeutics LLC; Tau Therapeutics LLC; Celerion, Inc.; Dana-Farber/Partners CancerCare, Inc.; LifeWatch, Inc.
Recruiting - verified March 2012 - Condition: Posttraumatic Stress Disorder (PTSD)
Interventions: Biological: Prazosin as first-line agent; Behavioral: Cognitive Behavioral Therapy for PTSD
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified February 2012 - Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: Propranolol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Conditions: Sturge Weber Syndrome; Port Wine Mark
Interventions: Drug: Timolol; Drug: Balanced salt ophthalmic solution
Sponsors: Wills Eye; Wills Eye; University of Medicine and Dentistry New Jersey
Not yet recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Lisinopril; Drug: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; American Foundation for AIDS Research
Recruiting - verified February 2012 - Conditions: Hot Flashes; Breast Cancer
Interventions: Drug: solifenacin; Drug: Clonidine
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Conditions: Ocular Hypertension; Open Angle Glaucoma
Interventions: Drug: AR-13324 Ophthalmic Solution 0.01%; Drug: AR-13324 Ophthalmic Solution 0.02%; Drug: AR-13324 Ophthalmic Solution 0.04%; Drug: AR-13324 Vehicle Ophthalmic Solution
Sponsors: Aerie Pharmaceuticals; Aerie Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Drug: 0.1% brimonidine tartrate and 0.01% bimatoprost; Drug: 0.01% bimatoprost and 0.2% hypromellose
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Condition: Primary Open Angle Glaucoma and Ocular Hypertension
Interventions: Drug: Stage 1 - ATS907 - Dose 1; Drug: Stage 1 - ATS907 - Dose 2; Drug: Stage 1 - ATS907 - Dose 3; Drug: Stage 1 - ATS907 - Dose 4; Drug: Stage 1 - Vehicle; Drug: Stage 2 - ATS907 - Dose A - to be selected from Stage 1; Drug: Stage 2 - ATS907 - Dose B - to be selected from Stage 1; Drug: Latanoprost 0.005%
Sponsors: Altheos, Inc.; Altheos, Inc.
Recruiting - verified January 2012 - Conditions: Alcohol Abuse; Posttraumatic Stress Disorder
Interventions: Drug: Prazosin; Drug: Placebo medication
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; National Institute on Alcohol Abuse and Alcoholism (NIAAA); VA Puget Sound Health Care System
Recruiting - verified December 2011 - Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Conditions: Preeclampsia; Pregnancy Induced Hypertension
Intervention: Drug: Irbesartan
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified May 2012 - Conditions: Heart Failure; Congestive Heart Failure
Interventions: Drug: Isosorbide Dinitrate; Drug: Isosorbide Dinitrate + Hydralazine; Drug: Placebo
Sponsors: Philadelphia Veterans Affairs Medical Center; Philadelphia Veterans Affairs Medical Center
Recruiting - verified January 2012 - Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified March 2012 - Condition: Glaucoma
Intervention: Drug: Travoprost/Timolol Maleate BAK-Free Fixed Combination
Sponsors: Alcon Research; Alcon Research
Recruiting - verified April 2012 - Conditions: Hypotension; Anesthesia
Intervention:
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center
Not yet recruiting - verified January 2012 - Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: atenolol; Drug: placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Forest Laboratories
Recruiting - verified January 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Intervention: Drug: Travoprost/timolol fixed combination (Travacom)
Sponsors: Alcon Research; Alcon Research
Not yet recruiting - verified April 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Intervention: Drug: Travoprost 0.004% without BAK containing Polyquad (PQ) preservative
Sponsors: Alcon Research; Alcon Research
Recruiting - verified March 2012 - Conditions: Stage 1 Hypertension; Stage 2 Hypertension
Interventions: Drug: Nebivolol and Valsartan 1; Drug: Nebivolol and Valsartan 2; Drug: Nebivolol and Valsartan 3; Drug: Nebivolol 1; Drug: Nebivolol 2; Drug: Valsartan 1; Drug: Valsartan 2; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C SR
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Device: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT); Device: Boston Scientific Intravascular Ultrasound
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Actelion
Recruiting - verified May 2012 - Conditions: Pulmonary Arterial Hypertension; Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: University of Florida; University of Florida; United Therapeutics
Recruiting - verified December 2011 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Intervention: Drug: Travoprost 0.004% without BAK containing Polyquad (PQ) preservative
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified December 2011 - Condition: Hypertension
Intervention: Drug: Lisinopril
Sponsors: Duke University; Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified March 2012 - Condition: Hypertension
Interventions: Drug: Metoprolol succinate; Drug: Nebivolol; Drug: Hydrochlorothiazide; Drug: DEFINITY®; Procedure: Non-invasive measurement of Cardiac Output (CO); Procedure: Flow mediated vasodilation; Procedure: Endothelial cell collection; Procedure: Microvascular perfusion assessment using Definity
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Forest Laboratories
Recruiting - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012 - Conditions: Nephropathy; Sickle Cell Anemia
Intervention: Drug: Losartan
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C SR
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified February 2012 - Conditions: Dental Anesthesia; Anesthesia, Local; Anesthesia, Reversal
Interventions: Drug: OraVerse; Other: Sham injection
Sponsors: Novocol Pharmaceutical of Canada, Inc.; Novocol Pharmaceutical of Canada, Inc.
Recruiting - verified May 2012 - Conditions: Generalized Anxiety Disorder (GAD); Anxiety, Separation; Phobia, Social
Interventions: Drug: SPD503 (extended-release Guanfacine hydrochloride); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Condition: Cannabis Dependence
Intervention: Drug: Guanfacine
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Not yet recruiting - verified December 2011 - Conditions: Cardiovascular Diseases; Coronary Disease; Coronary Artery Disease; Heart Diseases; Myocardial Ischemia
Interventions: Procedure: cardiac catheterization; Procedure: coronary artery bypass graft surgery; Procedure: percutaneous coronary intervention; Behavioral: Lifestyle; Drug: Medication
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); New York University; Vanderbilt University; Albany Stratton VA Medical Center; East Carolina University; Duke University; Harvard University; University of Missouri, Kansas City; Emory University; Cedars-Sinai Medical Center; Massachusetts General Hospital; University of Calgary; Columbia University; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Hypertension
Interventions: Drug: Metoprolol succinate; Drug: Nebivolol; Procedure: Forearm blood flow; Procedure: Microneurography; Procedure: Rhythmic handgrip exercise; Procedure: Lower body negative pressure; Drug: Angiotensin II
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Forest Laboratories
Recruiting - verified April 2012 - Conditions: Peripheral Artery Disease; Hypertension
Interventions: Drug: nebivolol; Drug: Metoprolol succinate
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Forest Laboratories
Recruiting - verified December 2011 - Condition: Ischemia Reperfusion Injury
Intervention: Drug: Treprostinil
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified January 2012 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus DiureticsCondition: Acute Decompensated Heart Failure
Interventions: Drug: Loop diuretics (furosemide, torsemide, bumetanide); Other: Ultrafiltration
Sponsors: University of Cincinnati; University of Cincinnati
Recruiting - verified November 2011 - Conditions: Open Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Travoprost (New Formulation); Drug: TRAVATAN
Sponsors: Alcon Research; Alcon Research
Recruiting - verified February 2012 - Conditions: Transplant; Failure, Kidney; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol succinate
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Forest Laboratories; Lahey Clinic
Recruiting - verified February 2012 - Conditions: Alcohol Dependence; Anxiety
Interventions: Drug: Doxazosin; Drug: Placebo
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified September 2011 - Conditions: Hypertension; Metabolic Syndrome
Intervention: Drug: Aliskerin/Valsartan and Rampiril
Sponsors: University of Michigan Health System; University of Michigan Health System; Novartis Pharmaceuticals
Recruiting - verified September 2011 - Conditions: Infantile Hemangioma; Very Low Birth Weight Infants; Prematurity
Interventions: Drug: topical 0.5% Timolol; Drug: Control (placebo) group
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Not yet recruiting - verified September 2011 - Condition: Glaucoma
Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Condition: Glaucoma
Intervention: Drug: 0.005% Latanoprost dosed once.
Sponsors: Nanduri, Padma, M.D., FACS; Nanduri, Padma, M.D., FACS
Not yet recruiting - verified August 2011 - Conditions: Hypertension; Renal Failure Chronic Requiring Hemodialysis; Fluid Overload
Interventions: Drug: Antihypertensive Agents; Other: Dry weight Challenge; Dietary Supplement: Extend dialysis treatment time and re-challenge estimated dry weight
Sponsors: University of New Mexico; University of New Mexico; Tufts Medical Center; Medical University of South Carolina; University of Pittsburgh
Recruiting - verified June 2011 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2012 - Conditions: Blunt Trauma; Penetrating Wound; Hemorrhagic Shock
Interventions: Drug: Sodium Chloride 0.9% Injection; Drug: Sodium Chloride 0.9% Injection
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012 - Conditions: Thiazide Induced Dysglycemia; Thiazide Induced Dyslipidemia
Intervention: Drug: Oral Glucose Tolerance Test
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Primary Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: OPA-6566; Drug: Placebo; Drug: Latanoprost
Sponsors: Acucela Inc.; Acucela Inc.; Otsuka Pharmaceutical Co., Ltd.
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: lisinopril; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Persistent Fetal Circulation Syndrome
Interventions: Drug: Bosentan; Drug: Matching placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Conditions: Prehypertension; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol; Drug: Placebo
Sponsors: University of Colorado, Boulder; University of Colorado, Boulder; Forest Laboratories
Recruiting - verified May 2012 - Condition: Methamphetamine Dependence
Intervention: Drug: Doxazosin extended release
Sponsors: University of Arkansas; University of Arkansas; National Institute on Drug Abuse (NIDA); Baylor College of Medicine
Recruiting - verified November 2011 - Condition: Sialorrhoea
Interventions: Drug: OC oral solution treatment A; Drug: OC oral solution treatment B; Drug: OC oral solution treatment C; Drug: OC oral solution treatment D
Sponsors: Orient Pharma Co., Ltd.; Orient Pharma Co., Ltd.
Recruiting - verified May 2012 - Conditions: Hypertension; Stage 2 Hypertension; Diabetes
Interventions: Drug: Valturna + amlodipine; Drug: valturna + placebo; Drug: Valturna + chlorthalidone
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: Brinzolamide 1% +Timolol 0.5% fixed combination; Drug: Brinzolamide 1% and Timolol 0.5%
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: Carvedilol; Drug: Placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; Mount Sinai School of Medicine
Recruiting - verified March 2012 - Condition: Cancer Survivor
Interventions: Drug: carvedilol; Other: placebo; Other: pharmacogenomic studies; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Glaucoma
Interventions: Drug: Brinzolamide/Timolol Maleate Fixed Combination (Azarga); Drug: Dorzolamide/Timolol Maleate Fixed Combination (Cosopt)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Glaucoma
Intervention: Drug: Travoprost/Timolol Maleate Fixed Combination
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Conditions: Open Angle Glaucoma; Ocular Hypertension
Intervention: Drug: AR-12286 0.5% Ophthalmic Solution
Sponsors: Aerie Pharmaceuticals; Aerie Pharmaceuticals
Recruiting - verified November 2011 - Condition: Glaucoma
Intervention: Drug: Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination ophthalmic solution (DUOTRAV)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified April 2012 - Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease; Eisenmenger's Syndrome
Intervention: Drug: Iloprost
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Actelion
Recruiting - verified June 2011 - Condition: Infantile Hemangiomas
Interventions: Drug: Timolol 0.5% topical; Drug: Mupirocin
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Society for Pediatric Dermatology
Recruiting - verified August 2011 - Condition: Glaucoma
Interventions: Drug: Travoprost; Drug: Latanoprost
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Alcon Research
Recruiting - verified April 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Drug: Brinzolamide 1% Eye drops, suspension BID (AZOPT); Drug: Brimonidine Tartrate
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Open-angle Glaucoma or Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Other: Vehicle for masking purposes; Drug: Brinzolamide 1% ophthalmic suspension (AZOPT); Drug: Brimonidine 0.2% ophthalmic solution
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Conditions: Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury
Interventions: Drug: IV Propranolol and Per Tube Clonidine; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Conditions: High Blood Pressure; Substance Abuse
Interventions: Other: Usual Care; Behavioral: Contingency Management
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011 - Conditions: Invasive Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Intervention: Drug: Propranolol (Inderal)
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Hypertension; Pure Autonomic Failure; Multiple System Atrophy
Interventions: Drug: Losartan; Drug: Captopril; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Treprostinil
Sponsors: Los Angeles Biomedical Research Institute; Los Angeles Biomedical Research Institute; United Therapeutics
Recruiting - verified February 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: inhaled prostacyclin; Drug: inhaled prostacyclin; Drug: prostacyclin; Drug: subcutaneous and intravenous prostacyclin; Drug: oral ERA; Drug: oral PDE5 inhibitors
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified January 2012 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: VT-122 (propranolol plus etodolac); Drug: Placebo
Sponsors: Vicus Therapeutics; Vicus Therapeutics
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Behavioral: No intervention; Behavioral: Electronically-measuring adherence to antihypertensive medications
Sponsors: Columbia University; Columbia University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011 - Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (Azarga)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Conditions: Hypertension, Grade 1; Hypertension Treatment; N of 1 Study Design; Hypertension
Interventions: Drug: Lisinopril; Drug: Hydrochlorothiazide
Sponsors: Scripps Translational Science Institute; Scripps Translational Science Institute
Recruiting - verified January 2012 - Condition: Cardiovascular Events
Interventions: Drug: Aliskiren and Amlodipine or HCTZ; Drug: Aliskiren; Drug: Amlodipine or HCTZ; Drug: Placebo
Sponsors: Novartis; Novartis; Population Health Research Institute
Recruiting - verified May 2012 - Condition: Benign Vascular Periocular Lesions
Intervention: Drug: topical Timolol
Sponsors: Loyola University; Loyola University
Recruiting - verified September 2011 - Conditions: Pregnant Women; Severe Hypertension
Intervention:
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center
Recruiting - verified April 2012 - Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Drug: Atomoxetine Hydrochloride; Drug: Placebo Comparator
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Hypertension
Intervention: Other: Favor one of two thiazides for new prescriptions & attempt target dose
Sponsors: VA Pharmacy Benefits Management Strategic Healthcare Group; VA Pharmacy Benefits Management Strategic Healthcare Group
Recruiting - verified September 2011 - Conditions: Hypertension; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: lisinopril; Drug: losartan potassium; Other: laboratory biomarker analysis; Drug: benazepril hydrochloride; Drug: ramipril
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Condition: Pervasive Development Disorders
Interventions: Drug: extended-release guanfacine; Other: placebo
Sponsors: Yale University; Yale University; Massachusetts General Hospital; Seattle Children's Hospital; University of California, Los Angeles; National Institute of Mental Health (NIMH)
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: bosentan; Drug: bosentan
Sponsors: Actelion; Actelion
Recruiting - verified November 2011 - Condition: Traumatic Brain Injury
Intervention: Drug: Propranolol
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified June 2010 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Gestational Hypertension
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Sunnybrook Research Institute
Recruiting - verified December 2011 - Condition: Postural Tachycardia Syndrome
Interventions: Drug: Losartan; Drug: Ascorbic Acid (Vitamin C); Drug: Normal Saline
Sponsors: New York Medical College; New York Medical College
Recruiting - verified December 2011 - Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Conditions: Opioid Related Disorders; Opioid Dependence; Opioid Addiction
Interventions: Drug: Buprenorphine/naloxone; Drug: Clonidine; Drug: Tramadol ER
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Condition: Non-treatment Seeking Methamphetamine Users
Interventions: Drug: oral placebo and methamphetamine 20mg po; Drug: Prazosin 1mg po and oral methamphetamine placebo; Drug: Prazosin 1mg po and Methamphetamine 20mg po
Sponsors: University of Arkansas; University of Arkansas; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Treatment Refractory Depression
Interventions: Drug: Ketamine; Drug: Clonidine; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Miami
Not yet recruiting - verified March 2012 - Conditions: Cocaine Dependence; Cocaine Withdrawal
Interventions: Drug: controlled release carvedilol; Drug: Placebo
Sponsors: University of Arkansas; University of Arkansas; National Institute on Drug Abuse (NIDA); Baylor College of Medicine
Recruiting - verified May 2012 - Condition: Neonatal Abstinence Syndrome
Interventions: Drug: Clonidine; Drug: Phenobarbital
Sponsors: Baystate Medical Center; Baystate Medical Center
Recruiting - verified April 2012 - Condition: Open-Angle Glaucoma
Interventions: Drug: bimatoprost ophthalmic formulation A, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation B, bimatoprost ophthalmic solution 0.03%; Drug: bimatoprost ophthalmic formulation C, bimatoprost ophthalmic solution 0.03%
Sponsors: Allergan; Allergan
Recruiting - verified December 2011 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Enalapril
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Intervention: Drug: Guanfacine (sustained release)
Sponsors: Neurology Group of Bergen County, P.A.; Neurology Group of Bergen County, P.A.; Shire Development LLC
Recruiting - verified July 2011 - Condition: Hepatorenal Syndrome Type 1
Interventions: Drug: Terlipressin; Drug: Placebo
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified May 2012 - Condition: Delirium
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: Memorial Health University Medical Center; Memorial Health University Medical Center
Recruiting - verified August 2011 - Condition: Endothelial Dysfunction
Interventions: Drug: Trimethaphan; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified April 2012 - Conditions: Attention Deficit Hyperactivity Disorder; Reading Difficulty or Disability
Interventions: Drug: Methylphenidate; Behavioral: Intensive reading instruction; Behavioral: Parent Training; Drug: Mixed Salt Amphetamine; Drug: Atomoxetine; Drug: Guanfacine
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy
Intervention: Drug: Coenzyme Q10 and Lisinopril
Sponsors: Cooperative International Neuromuscular Research Group; Cooperative International Neuromuscular Research Group; Department of Defense
Recruiting - verified November 2011 - Condition: Alzheimer's Disease
Interventions: Drug: Prazosin; Drug: Placebo
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; National Institute on Aging (NIA); VA Puget Sound Health Care System
Recruiting - verified February 2012 - Conditions: Hypertension; Pure Autonomic Failure; Multiple System Atrophy
Interventions: Drug: BQ123; Drug: BQ123; Drug: Bq123; Drug: BQ123; Drug: Saline
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Glaucoma
Intervention: Drug: Alphagan (brimonidine) 0.15%
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ACEI or ARB; Drug: Lisinopril
Sponsors: University of Virginia; University of Virginia
Recruiting - verified December 2011 - Conditions: Blood Pressure Control; Kidney Transplant Recipient
Intervention: Other: Medication Adjustment
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Recruiting - verified December 2011 - Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified December 2011 - Conditions: Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse
Interventions: Drug: Perindopril; Drug: Placebo; Drug: Candesartan
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Alcohol Dependence; PTSD
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified November 2011 - Conditions: Hypertension; Pure Autonomic Failure; Multiple System Atrophy
Interventions: Drug: Placebo; Drug: Nebivolol 5 mg; Drug: metoprolol tartrate 50 mg; Drug: Sildenafil25 mg
Sponsors: Vanderbilt University; Vanderbilt University; Forest Laboratories
Recruiting - verified May 2012 - Condition: Pulmonary Hypertension
Intervention: Drug: UT-15C
Sponsors: United Therapeutics; United Therapeutics
Recruiting - verified February 2012 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Eyelash Hypotrichosis; Alopecia Areata
Interventions: Drug: bimatoprost ophthalmic solution 0.03%; Drug: Vehicle Sterile Solution
Sponsors: Allergan; Allergan
Recruiting - verified November 2011 - Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Lofexidine and Dronabinol; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Alopecia; Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution; Drug: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Conditions: Stress Disorders, Post-Traumatic; Combat Disorders; Sleep Disorders
Interventions: Drug: prazosin hydrochloride; Drug: placebo
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; Department of Defense; VA Puget Sound Health Care System; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified March 2012 - Condition: Hemangioma of Infancy
Interventions: Drug: propranolol; Drug: Prednisolone
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified October 2011 - Condition: Acute Decompensated Heart Failure
Interventions: Drug: Intravenous Bolus Furosemide and Oral Metolazone; Drug: Intravenous Continuous Infusion Furosemide
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; University of Illinois
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Intervention: Drug: Nebivolol
Sponsors: Minneapolis Heart Institute Foundation; Minneapolis Heart Institute Foundation; Forest Laboratories
Recruiting - verified June 2011 - Condition: Sarcopenia
Interventions: Drug: Rapamycin; Other: Amino acid supplementation; Other: Low-intensity resistance exercise; Drug: Sodium nitroprusside; Device: Blood flow restriction cuff; Other: Low-intensity resistance exercise
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Conditions: Erectile Dysfunction; Lower Urinary Tract Symptoms
Interventions: Drug: Alfuzosin; Drug: Alfuzosin
Sponsors: Chesapeake Urology Research Associates; Chesapeake Urology Research Associates; Sanofi-Aventis
Recruiting - verified February 2012 - Conditions: Oxidative Stress; Endothelial Dysfunction
Interventions: Drug: ramipril (ACE inhibitor); Drug: valsartan (ARB); Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of Washington; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Lung Cancer
Intervention: Drug: Hydralazine and Valproic Acid
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes Mellitus; Vascular Disease
Interventions: Drug: Spironolactone; Drug: hydrochlorothiazide + potassium; Other: placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Healthy
Intervention: Drug: Atenolol (β-blocker)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified April 2012 - Conditions: Obesity; Hypertension
Interventions: Drug: eplerenone, amlodipine; Drug: eplerenone; Drug: eplerenone; Drug: amlodipine
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center
Recruiting - verified April 2012 - Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Conditions: Hypertension; Heart Failure
Interventions: Drug: Clevidipine butyrate injectable emulsion; Drug: standard of care IV antihypertensive treatment
Sponsors: The Medicines Company; The Medicines Company
Recruiting - verified January 2012 - Condition: Cardiomyopathy
Intervention: Drug: Metoprolol
Sponsors: University of Maryland; University of Maryland
Recruiting - verified October 2011 - Condition: Smoking
Interventions: Drug: guanfacine; Drug: placebo
Sponsors: Yale University; Yale University
Recruiting - verified January 2012 - Conditions: Orthostatic Intolerance; Postural Tachycardia Syndrome
Interventions: Drug: Propanolol; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Alcoholism
Interventions: Drug: Prazosin medication; Drug: Placebo medication
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; National Institute on Alcohol Abuse and Alcoholism (NIAAA); VA Puget Sound Health Care System; University of Washington
Recruiting - verified April 2011 - Condition: Myocardial Ischemia
Interventions: Drug: Metoprolol; Drug: Esmolol; Drug: Placebo
Sponsors: University of Oklahoma; University of Oklahoma
Recruiting - verified August 2011 - Condition: Hypertension
Intervention: Drug: losartan potassium
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Alcohol Dependence; Stress Disorders, Post-Traumatic
Intervention: Drug: Prazosin
Sponsors: Yale University; Elizabeth Ralevski
Recruiting - verified January 2012 - Conditions: Intracerebral Hemorrhage; Stroke; Hypertension
Intervention: Other: Blood pressure management policies
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Condition: Kidney Stones
Interventions: Drug: Alfuzosin; Drug: nifedipine; Drug: doxazosin; Drug: prazosin
Sponsors: United States Naval Medical Center, San Diego; United States Naval Medical Center, San Diego
Recruiting - verified April 2012 - Condition: Cocaine Dependence
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Condition: Sarcopenia
Interventions: Drug: Insulin Regular; Drug: L-NMMA; Drug: Sodium Nitroprusside; Other: mixed meal
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified May 2012 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension; PAH WHO Group I
Interventions: Drug: Sitaxsentan; Drug: Bosentan, Ambrisentan
Sponsors: West Penn Allegheny Health System; West Penn Allegheny Health System; National Institutes of Health (NIH); Baylor College of Medicine; Emory University; University of Chicago; Johns Hopkins University; Tufts Medical Center; Sir Mortimer B. Davis - Jewish General Hospital; London Health Sciences Centre; University of Maryland; University of California, San Francisco; University of Calgary; Chest Medical Associates; Columbia University; Lung Diagnostics, Ltd.; Duke University; University of California, Los Angeles; Latter Day Saints Hospital; Louisiana State University Health Sciences Center in New Orleans; Massachusetts General Hospital; Mayo Clinic; Medical College of Wisconsin; Southeastern Lung Care; Suncoast Lung Center; Children's Hospital Colorad; University Hospitals of Cleveland; University of Colorado, Denver; University of Michigan; University of Pittsburgh; University of Southern California; The University of Texas, Galveston; Vanderbilt University; Wayne State University; Ohio State University; University of Alabama at Birmingham; Washington University School of Medicine; Sentara Norfolk General Hospital; University of Texas Southwestern Medical Center; Bay Area Chest Physicians
Recruiting - verified January 2012 - Condition: Posttraumatic Stress Disorders
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: Yale University; Yale University; Department of Veterans Affairs; New York University
Recruiting - verified January 2012 - Condition: Ventricular Tachycardia
Interventions: Drug: clonidine; Drug: metoprolol
Sponsors: University of Iowa; University of Iowa; National Center for Research Resources (NCRR)
Recruiting - verified December 2007 - Conditions: Autonomic Nervous System Diseases; Orthostatic Hypotension
Interventions: Drug: droxidopa; Drug: placebo; Drug: alpha-methyldopa; Drug: carbidopa; Drug: metyrosine; Drug: levodopa; Drug: atomoxetine; Drug: metoclopramide
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study; Procedure: Collection of blood and tissues; Procedure: Radiology testing: DEXA, K+ counter, ultrasound, MRI; Drug: Humatrope; Drug: Ketoconazole; Drug: Oxandrolone; Drug: Propranolol; Drug: Oxandrolone and propranolol combined; Drug: Humatrope and propranolol combined; Drug: Placebo; Behavioral: Exercise--Hospital supervised intensive exercise program; Behavioral: Home exercise program
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; U.S. Department of Education; National Institutes of Health (NIH); Shriners Hospitals for Children
Recruiting - verified March 2012 - Conditions: Hemodialysis; Hypertension; Left Ventricular Hypertrophy
Interventions: Drug: Lisinopril; Drug: Atenolol
Sponsors: Indiana University; Indiana University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Conditions: Cocaine Dependent; Alcohol Dependent
Interventions: Drug: Guanfacine; Drug: Placebo
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Condition: Obesity
Interventions: Drug: Trimethaphan L-NMMA Insulin clamp; Drug: Saline, Insulin clamp
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Conditions: Myocardial Infarction; Cerebrovascular Accident; Death, Sudden, Cardiac
Intervention:
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Chronic Fatigue Syndrome; Orthostatic Intolerance; Postural Tachycardia Syndrome
Interventions: Other: Autonomic Function Testing; Other: Saline infusions; Drug: L-NMMA trimethaphan; Drug: methyldopa
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Cocaine Addictions
Interventions: Drug: sugar pill; Drug: carvedilol; Drug: Methadone
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Conditions: PTSD; Sleep Disorders
Interventions: Drug: prazosin; Other: placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Conditions: Kidney Transplant; Kidney Transplantation; Renal Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010 - Condition: Alcoholism
Intervention: Drug: mecamylamine
Sponsors: Yale University; Elizabeth Ralevski
Recruiting - verified January 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Bosentan; Drug: Sildenafil Citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cocaine Abuse; Heroin Abuse
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011 - Condition: Pulmonary Hypertension
Interventions: Drug: bosentan; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified February 2012 - Condition: Opioid-Related Disorders
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Conditions: Tachycardia; Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide; Drug: Atomoxetine; Other: Baseline (No Drug); Drug: Clonidine; Drug: Entacapone; Drug: Entacapone & Propranolol; Drug: Atomoxetine & Propranolol; Drug: Indomethacin; Drug: Mecamylamine; Drug: Isosorbide Dinitrate; Dietary Supplement: Melatonin; Drug: Midodrine; Drug: Modafinil; Drug: Octreotide; Radiation: Placebo; Drug: Propranolol; Drug: Modafinil & Propranolol; Drug: Sertraline; Procedure: IV Saline; Other: Drinking Water; Device: Breathing Device; Drug: memantine; Device: Abdominal binder
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Hyperlipidemia
Interventions: Drug: Tetraethylammonium (TEA); Drug: L-NMMA; Drug: Bradykinin; Drug: Nitroprusside; Drug: S-methyl-L-thiocitrulline (SMTC); Drug: Acetylcholine
Sponsors: Emory University; Emory University
Recruiting - verified May 2012 - Conditions: OBESITY; HYPERTENSION; PURE AUTONOMIC FAILURE; SHY-DRAGER SYNDROME
Interventions: Drug: Trimethaphan; Drug: Trimethaphan; Drug: Pseudoephedrine
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
 |
Antihypertensive Agents Clinical Trials |
